Patents Examined by Charanjit Aulakh
  • Tetradentate metal complexes with carbon group bridging ligands
    Patent number: 11653560
    Abstract: Platinum, palladium, and gold complexes suitable for use as phosphorescent emitters or as delayed fluorescent and phosphorescent emitters having the structure of Formula VIII.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: May 16, 2023
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Guijie Li
  • Nonmuscle myosin II inhibitors for substance use relapse
    Patent number: 11649234
    Abstract: The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: May 16, 2023
    Assignee: THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Courtney Miller, Patrick R. Griffin, Theodore Mark Kamenecka, Gavin Rumbaugh, Matthew Surman, Steve Young, Steven Duddy, Laszlo Radnai
  • EGFR inhibitors
    Patent number: 11639344
    Abstract: Provided herein are compounds, salts, solid forms, and pharmaceutical compositions that are related to EGFR inhibitors, such as N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, solid forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as cancer.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 2, 2023
    Assignee: INVENTISBIO CO., LTD.
    Inventors: Xing Dai, Yueheng Jiang
  • Methods for treating Huntington's disease
    Patent number: 11638706
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: May 2, 2023
    Assignee: PTC Therapeutics, Inc.
    Inventors: Suresh Babu, Anuradha Bhattacharyya, Seongwoo Hwang, Minakshi Jani, Young-choon Moon, Nadiya Sydorenko
  • Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as ?V integrin inhibitors
    Patent number: 11639353
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 2, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
    Patent number: 11639351
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: May 2, 2023
    Inventors: Jean-Christophe Andrez, Kristen Nicole Burford, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Qi Jia, Verner Alexander Lofstrand, Shaoyi Sun, Steven Sigmund Wesolowski, Michael Scott Wilson, Alla Yurevna Zenova
  • Benzothiazole compounds for the treatment of autoimmune diseases
    Patent number: 11639352
    Abstract: The present invention relates to compounds of formula (I), (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 2, 2023
    Assignee: Hoffman-La Roche Inc.
    Inventors: Wei Zhu, Ge Zou, Fabian Dey
  • Protein tyrosine phosphatase inhibitors
    Patent number: 11634417
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: James F. Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam W. Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren T. McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina E. Wong
  • Method of controlling depression in subjects treated for opioid dependence
    Patent number: 11617746
    Abstract: The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode. The method comprises treating the subject with an opioid agonist whilst managing their depression or depressive disorder using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 4, 2023
    Assignee: OREXO AB
    Inventor: Michael John Sumner
  • Combination therapy for the treatment of triple-negative breast cancer
    Patent number: 11607405
    Abstract: The invention provides methods for treating triple negative breast cancer (TNBC), by co-administration of a BET bromodomain inhibitor selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof, and a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be a PARP inhibitor, such as, e.g., talazoparib, olaparib or veliparib.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 21, 2023
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Eric Campeau, Laura Tsujikawa, Sanjay Lakhotia
  • Photoactive compound
    Patent number: 11600785
    Abstract: A compound of formula (I): EAG-EDG-EAG?? (I) wherein each EAG is an electron accepting group; and EDG is an electron-donating group of formula (IIa): The compound of formula (I) may be used in a photosensitive layer of an organic photodetector wherein the photosensitive layer comprises the compound of formula (I) and an electron donor. A photosensor may comprise the organic photodetector and a light source, e.g. a near infra-red light source.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: March 7, 2023
    Assignee: Sumitomo Chemical Company Limited
    Inventor: Kiran Kamtekar
  • JAK1 pathway inhibitors for the treatment of gastrointestinal disease
    Patent number: 11596632
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 7, 2023
    Assignee: Incyte Corporation
    Inventors: Krishnaswamy Yeleswaram, Paul Smith, Gregory F. Hollis
  • IRAK degraders and uses thereof
    Patent number: 11591332
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: February 28, 2023
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Matthew M. Weiss, Xiaozhang Zheng, Xiao Zhu
  • Phosphor-tetrazine compound and use thereof
    Patent number: 11584749
    Abstract: The present invention relates to a novel phosphor-tetrazine and a use thereof and, more particularly, provides a novel compound having high fluorescence amplification efficiency in various wavelength ranges by using a compound having a novel core skeleton called tert-butyl (3-(7-(6-methyl-1,2,4,5-tetrazin-3-yl)-3-oxo-9-phenyl-1H-pyrrolo[3,4-b]indolizin-2(3H)-yl)propyl)carbamate.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 21, 2023
    Assignees: Spark Biopharma, Inc., Seoul National University R&DB Foundation
    Inventors: Seung Bum Park, Young Jun Lee
  • Spirocyclic compounds
    Patent number: 11584748
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 21, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • MASP-2 inhibitors and methods of use
    Patent number: 11584714
    Abstract: The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: February 21, 2023
    Assignee: OMEROS CORPORATION
    Inventors: Neil S. Cutshall, Jennifer Lynn Gage, Franz A. Gruswitz, Juhienah Khalaf, Thomas L. Little, Markus Metz, Jeremiah H. Nguyen, Peter Kurt Nollert von Specht, Jennifer Tsoung, Michael Cicirelli, Sara Rebecca Goldstein, Santosh Kumar Keshipeddy, Do Yeon Kwon, Robert Huerta Lemus, Sudheer Babu Vaddela
  • Organic luminescent material containing 6-silyl-substituted isoquinoline ligand
    Patent number: 11581498
    Abstract: An organic light-emitting material contains a 6-silyl-substituted isoquinoline ligand. The organic light-emitting material is a metal complex containing a 6-silyl-substituted isoquinoline ligand and may be used as a light-emitting material in a light-emitting layer of an organic electroluminescent device. These new complexes can provide redder and saturated emission and meanwhile demonstrate a significantly improved lifetime and efficient and excellent device performance. Further disclosed are an electroluminescent device and a compound formulation including the metal complex.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: February 14, 2023
    Assignee: BEIJING SUMMER SPROUT TECHNOLOGY CO., LTD.
    Inventors: Nannan Lu, Zhihong Dai, Cuifang Zhang, Qi Zhang, Chi Yuen Raymond Kwong, Chuanjun Xia
  • Inhibiting mutant IDH-1
    Patent number: 11576906
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: February 14, 2023
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
  • Heterocyclic RIP1 inhibitory compounds
    Patent number: 11578078
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 14, 2023
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11578072
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 14, 2023
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan